The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
In recent decades, non-alcoholic fatty liver disease (NAFLD) has become the most common liver disease in the Western world, and the occurrence of its complications, such as hepatocellular carcinoma (HCC), has rapidly increased. Obesity and diabetes are considered not only the main triggers for the development of the disease, but also two independent risk factors for HCC. Single nucleotide polymorphisms (such as PNPLA3, TM6SF2 and MBOAT7) are related to the susceptibility to the development of HCC and its progression. Therefore, an appropriate follow-up of these patients is needed for the early diagnosis and treatment of HCC. To date, international guidelines recommend the use of ultrasonography with or without alpha-fetoprotein (AFP) in patients with advanced fibrosis. Furthermore, the use of non-invasive tools could represent a strategy to implement surveillance performance. In this review, we analyzed the main risk factors of NAFLD-related HCC, the validated screening methods and the future perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287 · cited 1×
“[2] showed an increased overall mortality (HR 1.”
BackgroundKozlitina, J., Smagris, E., Stender, S., Nordestgaard, B. G., Zhou, H. H., Tybjærg-Hansen, A., Vogt, T. F., Hobbs, H. H., & Cohen, J. C. (2014) · Nature Genetics · doi:10.1038/ng.2901 · Cited by 1,234
Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035
Speliotes, E. K., Yerges-Armstrong, L. M., Wu, J., Hernaez, R., Kim, L. J., Palmer, C. D., Gudnason, V., Eiriksdottir, G., Garcia, M. E., Launer, L. J., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001324 · Cited by 984
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease
Kanwal, F., Kramer, J. R., Mapakshi, S., Natarajan, Y., Chayanupatkul, M., Richardson, P. A., Li, L., Desiderio, R., Thrift, A. P., Asch, S. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.024 · Cited by 795 · cited 1×
“In this sense, a retrospective multicenter cohort study conducted in 130 hospitals of Veterans Health Administration in the USA compared 296,707 US-proven NAFLD patients with 296,707 age- and sex-matched controls [54].”
BackgroundFriedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671 · cited 1×
“Cenicriviroc, a dual inhibitor of fibrosis-promoting CCR2/CCR5 reduced liver fibrosis in a phase 2 trial (CENTAUR) [94], and is now being tested in a follow-up phase 3 trial (AURORA, NCT03028740).”
BackgroundMazzaferro, V., Sposito, C., Zhou, J., Pinna, A. D., De Carlis, L., Fan, J., Cescon, M., Di Sandro, S., Yi-feng, H., Lauterio, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.09.025 · Cited by 655 · cited 1×
“On the other hand, AFP is a useful tool for the prediction of the prognosis of patients with HCC [47].”
Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648 · cited 1×
“The development of HCC in patients with NAFLD without cirrhosis suggests a NAFLD-specific mechanism of carcinogenesis that is probably independent of hepatic fibrosis [68].”
BackgroundLiu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623 · cited 1×
“Similar to the PNPLA3 I148M variant, the rs58542926 C > T variant in the TM6SF2 gene, encoding an E167K mutation, was shown to be associated with hepatic steatosis and also with increased risk of progressive liver disease and fibrosis [32–35], but its direct role in HCC predisposition is disputed [35,36].”
ResultPiscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., Bellentani, S., & on behalf of the HCC‐NAFLD Italian Study Group (2016) · Hepatology · doi:10.1002/hep.28368 · Cited by 604
Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team
Dyson, J., Jaques, B., Chattopadyhay, D., Lochan, R., Graham, J., Das, D., Aslam, T., Patanwala, I., Gaggar, S., Cole, M., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.011 · Cited by 603 · cited 1×
“Several international studies [4,5] conducted in the last decade confirmed this evidence.”
BackgroundBuch, S., Stickel, F., Trépo, E., Way, M., Herrmann, A., Nischalke, H. D., Brosch, M., Rosendahl, J., Berg, T., Ridinger, M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3417 · Cited by 565 · cited 1×
“The rs641738 C > T variant of the MBOAT7 gene was identified in alcoholic-related cirrhosis and subsequently confirmed to increase risk of hepatic steatosis, progressive liver disease in NAFLD [37,38], and HCC risk in non-cirrhotics with NAFLD, as well as non-cirrhotic chronic hepatitis C and alcoholic liver disease […”
BackgroundPirola, C. J., Fernández Gianotti, T., Castaño, G. O., Mallardi, P., San Martino, J., Mora Gonzalez Lopez Ledesma, M., Flichman, D., Mirshahi, F., Sanyal, A. J., & Sookoian, S. (2015) · Gut · doi:10.1136/gutjnl-2014-306996 · Cited by 564
Liu, Y.-L., Patman, G. L., Leathart, J. B. S., Piguet, A.-C., Burt, A. D., Dufour, J.-F., Day, C. P., Daly, A. K., Reeves, H. L., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.02.030 · Cited by 549 · cited 2×
“8% UK and Switzerland Age, sex, BMI, diabetes, cirrhosis [29]”
BackgroundResultObesity and Cancer Risk: Recent Review and Evidence
Basen-Engquist, K., & Chang, M. (2011) · Current Oncology Reports · doi:10.1007/s11912-010-0139-7 · Cited by 439 · cited 1×
“Large cohort studies showed a strong association between obesity and cancer incidence (both overall and for specific sites) [12].”
BackgroundStine, J. G., Wentworth, B. J., Zimmet, A., Rinella, M. E., Loomba, R., Caldwell, S. H., & Argo, C. K. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14937 · Cited by 336
Kawamura, Y., Arase, Y., Ikeda, K., Seko, Y., Imai, N., Hosaka, T., Kobayashi, M., Saitoh, S., Sezaki, H., Akuta, N., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.327 · Cited by 280
Belli, L. S., Perricone, G., Adam, R., Cortesi, P. A., Strazzabosco, M., Facchetti, R., Karam, V., Salizzoni, M., Andujar, R. L., Fondevila, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.010 · Cited by 251 · cited 1×
“3% with HCC) between January 2007 to June 2017 [9].”
BackgroundKim, D., Li, A. A., Gadiparthi, C., Khan, M. A., Cholankeril, G., Glenn, J. S., & Ahmed, A. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.008 · Cited by 223
Mann, D. A. (2014) · Hepatology · doi:10.1002/hep.27131 · Cited by 153
Pais, R., Fartoux, L., Goumard, C., Scatton, O., Wendum, D., Rosmorduc, O., & Ratziu, V. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14261 · Cited by 129 · cited 1×
“Several international studies [4,5] conducted in the last decade confirmed this evidence.”
BackgroundFrom obesity to cancer: a review on proposed mechanisms
Tahergorabi, Z., Khazaei, M., Moodi, M., & Chamani, E. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3229 · Cited by 118
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients
Ma, S., Zheng, Y., Xiao, Y., Zhou, P., & Tan, H. (2017) · Medicine · doi:10.1097/md.0000000000006888 · Cited by 89 · cited 1×
“52) compared to the control group [92].”
Singal, A. G., Tiro, J. A., Murphy, C. C., Marrero, J. A., McCallister, K., Fullington, H., Mejias, C., Waljee, A. K., Pechero Bishop, W., Santini, N. O., et al. (2019) · Hepatology · doi:10.1002/hep.30129 · Cited by 89
Cited by
Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma
Hanif, H., Ali, M. J., Susheela, A. T., Khan, I. W., Luna-Cuadros, M. A., Khan, M. M., & Lau, D. T.-Y. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i2.216 · Cited by 354
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
“Additional genes, including TM6SF2 , MBOAT7 and HSD17B13 , have been shown to have a substantial role in influencing the likelihood of developing steatosis, fibrosis and HCC in patients with NAFLD and ALD 72,168,169 (Table 2).”
BackgroundJohnson, N. D., Wu, X., Still, C. D., Chu, X., Petrick, A. T., Gerhard, G. S., Conneely, K. N., & DiStefano, J. K. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01129-y · Cited by 43
Pennisi, G., Enea, M., Romero‐Gomez, M., Viganò, M., Bugianesi, E., Wong, V. W. ‐., Fracanzani, A. L., Sebastiani, G., Boursier, J., Berzigotti, A., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16763 · Cited by 43
Self-citation
Metadata
- Authors
- Pennisi, G., Celsa, C., Giammanco, A., Spatola, F., & Petta, S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-11-09
- Volume
- 20
- Issue
- 22
- Pages
- 5613
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2989113496
- Cited by
- 55
- References
- 26
- FWCI
- 6.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.